Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Peramivir: Phase II data

In a double-blind Phase II trial in 313 evaluable patients, peramivir failed to significantly reduce median time to alleviation of

Read the full 208 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE